Review



cal33-shcontrol cells  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Jackson Laboratory cal33-shcontrol cells
    Cal33 Shcontrol Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cal33-shcontrol+cells/cal33+shcontrol+cells/pm37501404-107-2-41
    Average 90 stars, based on 1 article reviews
    cal33-shcontrol cells - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Expressing:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Activation Assay:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Activity Assay:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Protein Array:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Western Blot:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Immunofluorescence:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Staining:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Immunohistochemical staining:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Proliferation Assay:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Derivative Assay:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    In Vitro:

    Article Title: Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
    Article Snippet: To generate CAL33 tumor-bearing mice, CAL33-shControl and CAL33-shEGFR-3 cells (3 9 106 and 5 9 106 cells, respectively) were suspended in 100 lL of PBS and injected subcutaneously into the right and left flanks of 6-week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).

    Article Title: Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Article Snippet: To generate CAL33 tumor‐bearing mice, CAL33‐shControl and CAL33‐shEGFR‐3 cells (3 × 10 6 and 5 × 10 6 cells, respectively) were suspended in 100 μL of PBS and injected subcutaneously into the right and left flanks of 6‐week‐old female NSG mice (NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Labs, Bar Harbor, ME, USA).



    Similar Products

    cal33-shcontrol cells  (Jackson Laboratory)
    90
    Jackson Laboratory cal33-shcontrol cells
    Cal33 Shcontrol Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cal33-shcontrol+cells/cal33+shcontrol+cells/pm37501404-107-2-41
    Average 90 stars, based on 1 article reviews
    cal33-shcontrol cells - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results